source
- AbbVie reports 60% reduction in progression risk for myeloma drug etentamig in Phase 3 trialAbbVie announced results from a Phase 3 study of its T cell engager etentamig in patients with multiple myeloma. The trial demonstrated a 60% relative reduction in the risk of disease progression…
- Scaling CAR-T: The hidden challenge of thousands of patient-specific manufacturing runsLegend Biotech and Johnson & Johnson’s Carvykti therapy illustrates the personal connection patients have with CAR-T, but also its unique operating model where each commercial dose is linked to an…